Citable company snapshot
Edwards Lifesciences's latest SEC-sourced 2026-06-30 period shows $1.74B in revenue and $241.90M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue | Jun 30, 2026 | $1.74B | $1.65B | +5.6% |
| Gross Profit | Jun 30, 2026 | $1.35B | $1.29B | +4.9% |
| Operating Income | Jun 30, 2026 | $513.20M | $477.60M | +7.5% |
| Net Income | Jun 30, 2026 | $241.90M | $380.70M | -36.5% |
| Operating Cash Flow (computed) | Jun 30, 2026 | $651.90M | $43.80M | +1388.4% |
| Free Cash Flow (computed) | Jun 30, 2026 | $585.00M | $-21.10M | +2872.5% |
Source: SEC EDGAR financial statements; period Jun 30, 2026; filed Aug 4, 2026; accession 0001099800-26-000043.
EW company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the overview view.
A factual guide to market capitalization, shares outstanding, public float, and why share-count definitions matter.
A factual guide to dividends, share repurchases, and how companies can return capital to shareholders.
A factual guide to book value, tangible book value, and balance-sheet net worth measures.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.